Clinic Software← All companies
Liberate Bio
driving cells directly in the body
health AI/biotechgene therapygenetic medicines
StageSeed
Raised$31M
Founded2022
Employees11
LocationBoston, MA
Business modelnot explicitly stated
About
Today, the biggest bottleneck in genetic medicine isn’t the power of mRNA, CRISPR, or gene therapy—it’s that we can’t get these medicines anywhere but the liver. Our RAPTOR™ platform is the first AI-driven system that makes extrahepatic genetic medicine scalable. Unlike the slow, inefficient trial-and-error process that dominates biotech, we directly test hundreds of novel lipid nanoparticles (LNPs) in non-human primates (NHPs) at 100 times lower cost, generating real-world, human-relevant data.
Product
- Value proposition
- A scalable in vivo delivery platform (RAPTOR) that identifies delivery solutions to target specific cell populations, enabling genetic payloads to reach previously inaccessible cells for therapeutic reprogramming.
- Target customers
- biotech and pharmaceutical companies, research institutions
Founders
- Michael J. Mitchell
- Nessan Bermingham
- Theresa M. Reineke
- Stephen Scully
Categories
Products
RAPTOR platformLiberate Programs (oncology and autoimmunity)
Key features
in vivo delivery platformcell-specific targetingreprogramming of immune cellsdiscovery system for delivery solutionsfocus on bone marrow and myeloid lineages
Technologies
in vivo deliverycell targetinggenetic payload deliverybiologic payloadsplatform discovery
Target conditions
hematologic cancersautoimmune diseases
Care settings
in vivo (in the body)clinical development settingsresearch/biotech labs
Investors
Khosla Ventures
News
- Exclusive: Lipid nanoparticle startup emerges with $31M from... · 2025-10-15T00:00:00.000Z
- Liberate Bio gains licences for myeloid-specific CAR design patents · 2026-03-06T10:11:53.000Z
- Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs · 2026-03-05T00:00:00.000Z
- Liberate Bio Presents New Preclinical Data Supporting First Clinical Evaluation of In Vivo CAR-M Program LIB820 in Autoimmune Disease | Morningstar · 2026-05-13T11:00:00.000Z
- Liberate Bio Presents New Preclinical Data Supporting First Clinical... · 2026-05-13T00:00:00.000Z
- Liberate Bio Demonstrates First In Vivo CAR-M–Mediated B-Cell Depletion in Non-Human Primates · 2025-10-15T15:45:00.000Z
